Navigation Links
Vulnerability to Anthrax Varies Widely: Study
Date:2/6/2012

MONDAY, Feb. 6 (HealthDay News) -- People's susceptibility to anthrax toxin is determined by their genes and can vary greatly among individuals, a new study says.

Anthrax is an infectious disease widely regarded as a potential bioterrorism weapon.

Stanford University School of Medicine researchers analyzed immune cells from 234 people and found that the cells of three of the people were virtually insensitive to anthrax toxin, while the cells of others were hundreds of times more sensitive than those of other people.

The findings could help lead to new treatments and could also have important implications for U.S. national security, according to a university news release. For example, people known to be more resistant could act as first-line responders in an anthrax bioterrorism attack.

The study appears online Feb. 6 in the journal Proceedings of the National Academy of Sciences.

"This research offers an important proof of principle. They've showed that genetically determined variations in the level of expression of a human protein can influence the susceptibility of host cells to anthrax toxin," Dr. David Relman said in the release.

Relman is a professor of microbiology and immunology and of medicine at Stanford, chair of the Institute of Medicine's Forum on Microbial Threats and a member of the U.S. Department of Health and Human Service's National Science Advisory Board for Biosecurity. He was not involved in the study.

"The findings also provide a possible means for predicting who is likely to become seriously ill after exposure, which could be extremely useful when faced with a large number of exposed people, such as was the case during the 2001 anthrax attacks," Relman said. (A week after the 9/11 attacks, letters carrying anthrax spores were mailed within the United States, killing five people and infecting 17 others.)

"Finally, they could lead to the development of novel trea
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Signaling pathways point to vulnerability in breast cancer stem cells
2. PTSD: The serotonin system influences vulnerability and treatment
3. Anthrax Vaccine Shows Promise in Monkeys
4. Anthrax capsule vaccine protects monkeys from lethal infection
5. Natural killer cells could be key to anthrax defense
6. Community storage of anthrax-preventing antibiotics should be determined by state
7. Bacillus anthracis and Anthrax
8. Poll: Hypothetical anthrax attack and antibiotics
9. Rate of follow-up surgeries after partial mastectomy varies greatly
10. Treatment of rectal cancer varies enormously between different European countries
11. Thyroid cancer treatment varies by hospital, U-M study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Vulnerability to Anthrax Varies Widely: Study
(Date:7/30/2014)... 2014 Good Neighbor Community Services ... upcoming episode of Innovations with Ed Begley Jr, ... and show times TBA. , In this segment, ... Services’ vision to redefine the traditional approach to ... services. Through passion, innovation, determination, excellence, and collaboration, ...
(Date:7/30/2014)... SF Cable, distributor of the highest ... on the internet with guaranteed customer satisfaction announces the ... two colors. These lightning cords are MFI certified to ... quality SF Cable Lightning to USB Cables ... faster charging and syncing. Compatible with the iPhone 5S/5C/5 ...
(Date:7/30/2014)... Hamilton Facial Plastic Surgery ... Carmel office on July 30th. After months of planning, ... to the state-of-the-art suite, located only steps away from ... allow for one-on-one patient comfort, shorter wait times, and ... Dr. Hamilton’s new office-suite will continue to provide the ...
(Date:7/30/2014)... ... ... ... , UCLA researchers interviewed people with diverticulitis and confirmed that many suffer psychological and physical symptoms long ... , a UCLA team led by Dr. Brennan Spiegel interviewed patients in great detail about the symptoms they experience weeks, months or ...
(Date:7/30/2014)... York (PRWEB) July 30, 2014 As ... http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgeries continues to grow, Bernstein ... voice to those calling for a ban on uterine ... Debra Valverde was diagnosed with leiomyosarcoma following a hysterectomy ... a year of her diagnosis, the aggressive cancer had ...
Breaking Medicine News(10 mins):Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 4
... to Better ... of Treatment Options, WASHINGTON, Nov. 2 Today, ... organization for interventional cardiology, announced the,launch of Seconds Count, ... for an authoritative resource about cardiovascular disease and,treatment. The ...
... Kensey Nash Corporation,(Nasdaq: KNSY ) today announced ... Coherence Domain Reflectometry Guidewire, from Lawrence,Livermore National Security, ... to its chronic total occlusion (CTO) platform.,The patent ... it to sense locations, thickness, and structure of ...
... CPR, assistance, measuring pain medication effectiveness, improving cancer ... ... A novel way to treat cancer,has won the top honor at the ... Fame Foundation. Ian,Cheong of Johns Hopkins University was announced as the grand ...
... of the time,that sales people should be spending with the ... Pharmaceutical sales directors agree the answer is ,too much time, ... - or 6 weeks per rep,per year - is unnecessary ... recent research study by Best Practices, LLC. But yet,understanding and ...
... LAWRENCE, Mass., Nov. 2 NxStage Medical, Inc.,(Nasdaq: ... portable,kidney dialysis machine, today announced its financial results for ... the third quarter of 2007 were $11.6 million, compared ... increase of 111%. Revenues in,the chronic home dialysis market ...
... demonstrates >99% mean decrease in HCV RNA ... with no serious adverse events-, PRINCETON, ... results of a 14-day Phase 1 multiple ascending,dose monotherapy study of ... being presented as a "late-breaker" abstract at,the 58th Annual Meeting of ...
Cached Medicine News:Health News:New Web Site Helps Patients Navigate Heart Disease Treatment Options 2Health News:New Web Site Helps Patients Navigate Heart Disease Treatment Options 3Health News:Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform 2Health News:Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform 3Health News:Collegiate Inventors Competition(R) Announces Winners for 2007 2Health News:Collegiate Inventors Competition(R) Announces Winners for 2007 3Health News:Collegiate Inventors Competition(R) Announces Winners for 2007 4Health News:Collegiate Inventors Competition(R) Announces Winners for 2007 5Health News:New Pharmaceutical Sales Force Communication Metrics: Nearly 6 Weeks of Sales Time per Rep Wasted Each Year 2Health News:NxStage Medical Reports Third Quarter 2007 Results 2Health News:NxStage Medical Reports Third Quarter 2007 Results 3Health News:NxStage Medical Reports Third Quarter 2007 Results 4Health News:NxStage Medical Reports Third Quarter 2007 Results 5Health News:NxStage Medical Reports Third Quarter 2007 Results 6Health News:NxStage Medical Reports Third Quarter 2007 Results 7Health News:NxStage Medical Reports Third Quarter 2007 Results 8Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 2Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 3Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 4Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 5
(Date:7/30/2014)... , July 30, 2014  InnoPharma, Inc. today ... 10mg/vial (the generic equivalent of Zyprexa® injection), in Canada.  ... and disturbed behaviors in patients with schizophrenia or bipolar ... generic injectable drug, InnoPharma has entered into an agreement ... Canada will make, use, sell, market and distribute ...
(Date:7/30/2014)... Cynosure, Inc. (NASDAQ: CYNO ... non-invasive and minimally invasive applications, today announced that the Board ... and Chief Financial Officer Timothy W. Baker to ... will continue to serve as CFO and will take the ... Chairman and Chief Executive Officer. "Tim has ...
(Date:7/30/2014)... SAN DIEGO , July 30, 2014 /PRNewswire/ ... ) announced today that an article based on post-hoc analyses ... "Early Weight Loss While on Lorcaserin, Diet, and Exercise as ... in the online issue of Obesity , the official ... these analyses was to identify whether there is an early ...
Breaking Medicine Technology:InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
... Mass., Nov. 17 Decision Resources, one of the world,s ... finds that, driven by the continued dominance of opioids that ... cancer pain drug market will increase from $2.3 billion in ... France, Germany, Italy, Spain, the United Kingdom and Japan. , ...
... , DURHAM, N.C., Nov. 17 Oxygen ... the company has begun shipping Dermacyte(TM) Oxygen Concentrate Gel ... The shipments, which are going out today, cover orders ... milestone event for our company - actually shipping a ...
Cached Medicine Technology:The Cancer Pain Drug Market, Driven by the Continued Dominance of Opioids, Will Increase From $2.3 Billion in 2008 to $3.7 Billion in 2018 2Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers 2
... ART Aerosol Resistant Tips offer a ... ART Tips are designed for applications such ... studies. In addition, ART Tips are excellent ... and forensic studies. ART Tips prevent aerosol ...
... Binding, Graduated Pipet Tips - 2l - 200l. ... referenced. Produced & packaged completely by automation. RNAse ... packaged 96 tips/rack and 10 racks/cs. AVR2 is ... racks/cs. AVR3 is the Stacked Rack packaged 96 ...
... orifice tip, the Finntip Wide is designed ... macromolecules like genomic DNA. This tip eliminates ... It is excellent for use with extremely ... inside diameter of the orifice is 1.1 ...
... been designed to optimize the accuracy and ... tip products is widely recognized by customers ... been extended over the years and now ... special tips including filter tips, certified pure ...
Medicine Products: